ArticleJournal of the American Heart Association2026
Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with atrial fibrillation (AF) remain exposed to residual thromboembolic and cardiovascular risk despite oral anticoagulation. The Atherogenic Index of Plasma (AIP) reflects atherogenic burden, but its prognostic value in anticoagulated AF is uncertain.
methodsThis prospective cohort study included consecutive outpatients with AF initiating oral anticoagulation between January 2016 and November 2021. AIP was calculated from baseline triglyceride and high-density lipoprotein cholesterol levels. Patients were stratified into low and high AIP groups using an outcome-driven cut-off. Primary outcomes were thromboembolic events and major adverse cardiovascular events. Secondary outcomes included cardiovascular and all-cause death. Associations were assessed using restricted cubic spline models and multivariable Cox regression analyses adjusted for AF-related comorbidities and concomitant therapies.
resultsAmong 2535 patients (52.4% women; median age, 76 years [interquartile range, 69-82 years]) followed up for 1.81±0.50 years, thromboembolic events occurred in 187 (7.4%) and major adverse cardiovascular events in 254 (10.0%). Restricted cubic spline models showed significant nonlinear associations with thromboembolic events (overall
conclusionsElevated AIP identifies anticoagulated patients with AF at increased residual thromboembolic and cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.